Page 187 - MSU Digital Book

28. Maes B, Hadaya K, de Moor B, Cambier P, Peeters P, de Meester J, et al. Severe

diarrhea in renal transplant patients: results of the DIDACT study. Am J Transplant.
2006;6:1466-72.
29. Prednisolone. [accessed 29 March 2020]. Available from: https://www.accessdata.

fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf.
30. Rituxan . [accessed 29 March 2020]. Available from: https://www.accessdata.fda.
®
gov/drugsatfda_docs/label/2018/103705s5450lbl.pdf.
®
31. Rapamune . [accessed 29 March 2020]. Available from: https://www.accessdata.
fda.gov/drugsatfda_docs/label/2017/021083s059,021110s076lbl.pdf.

32. Prograf . [accessed 29 March 2020]. Available from: https://www.accessdata.fda.
®
gov/drugsatfda_docs/label/2012/050709s031lbl.pdf.

33. Advagraf . [accessed 29 March 2020]. Available from: https://www.accessdata.fda.
®
gov/drugsatfda_docs/label/2018/204096s005lbl.pdf.
34. Woywodt A, Delargy M, Thain Z. Different preparations of tacrolimus and Medication

Errors. American Journal of Transplantation. 2008;8:962.
35. Saif I, Delargy M, Thain Z, Woywodt A. Potentially serious medication errors with

a new once-daily preparation of tacrolimus (Advagraf™). NDT Plus. 2009;2:193-4.
36. Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, et
al. Personalized tacrolimus doses determined by CYP3A5 genotype for induction

and maintenance phases of kidney transplantation. Clin Ther. 2013;35:1762-9.
37. Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, et al.

Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus
report. Ther Drug Monit. 2019;41:261-307.
38. Hochleitner BW, Bösmüller C, Nehoda H, Frühwirt M, Simma B, Ellemunter H, et

al. Increased tacrolimus levels during diarrhea. Transpl Int. 2001;14:230-3.
39. Tatro D. Drug interaction facts. Wolters Kulwer Health. Missouri.US. 2014.

162